Compare EVH & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVH | NGEN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 317.6M |
| IPO Year | 2015 | N/A |
| Metric | EVH | NGEN |
|---|---|---|
| Price | $2.98 | $4.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $7.93 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 100.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,957,000.00 | N/A |
| Revenue This Year | $33.03 | N/A |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $3.73 |
| 52 Week High | $11.92 | $5.93 |
| Indicator | EVH | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 40.23 |
| Support Level | $2.53 | $3.76 |
| Resistance Level | $4.20 | $4.44 |
| Average True Range (ATR) | 0.26 | 0.26 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 42.68 | 30.00 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.